vs

Side-by-side financial comparison of Cheer Holding, Inc. (CHR) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

Zai Lab Ltd is the larger business by last-quarter revenue ($127.1M vs $71.0M, roughly 1.8× Cheer Holding, Inc.). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs -0.1%).

Cheer Holding, Inc. is a diversified holding company primarily operating in the Chinese market, with core business segments covering early childhood education services, mobile lifestyle platforms, digital content offerings, and integrated consumer solutions for households and enterprise partners across multiple demand scenarios.

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

CHR vs ZLAB — Head-to-Head

Bigger by revenue
ZLAB
ZLAB
1.8× larger
ZLAB
$127.1M
$71.0M
CHR
Growing faster (revenue YoY)
ZLAB
ZLAB
+17.2% gap
ZLAB
17.1%
-0.1%
CHR

Income Statement — Q2 FY2025 vs Q4 FY2025

Metric
CHR
CHR
ZLAB
ZLAB
Revenue
$71.0M
$127.1M
Net Profit
$7.8M
Gross Margin
70.7%
51.0%
Operating Margin
11.7%
-54.6%
Net Margin
10.9%
Revenue YoY
-0.1%
17.1%
Net Profit YoY
-37.5%
EPS (diluted)
$0.67
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CHR
CHR
ZLAB
ZLAB
Q4 25
$127.1M
Q3 25
$115.4M
Q2 25
$71.0M
$109.1M
Q1 25
$105.7M
Q4 24
$108.5M
Q3 24
$101.8M
Q2 24
$71.1M
$100.1M
Q1 24
$87.1M
Net Profit
CHR
CHR
ZLAB
ZLAB
Q4 25
Q3 25
$-36.0M
Q2 25
$7.8M
$-40.7M
Q1 25
$-48.4M
Q4 24
Q3 24
$-41.7M
Q2 24
$12.4M
$-80.3M
Q1 24
$-53.5M
Gross Margin
CHR
CHR
ZLAB
ZLAB
Q4 25
51.0%
Q3 25
59.5%
Q2 25
70.7%
60.6%
Q1 25
63.6%
Q4 24
61.5%
Q3 24
64.1%
Q2 24
73.4%
64.9%
Q1 24
61.4%
Operating Margin
CHR
CHR
ZLAB
ZLAB
Q4 25
-54.6%
Q3 25
-42.3%
Q2 25
11.7%
-50.3%
Q1 25
-53.3%
Q4 24
-62.6%
Q3 24
-66.6%
Q2 24
16.4%
-76.0%
Q1 24
-80.7%
Net Margin
CHR
CHR
ZLAB
ZLAB
Q4 25
Q3 25
-31.2%
Q2 25
10.9%
-37.3%
Q1 25
-45.8%
Q4 24
Q3 24
-40.9%
Q2 24
17.5%
-80.2%
Q1 24
-61.4%
EPS (diluted)
CHR
CHR
ZLAB
ZLAB
Q4 25
$-0.05
Q3 25
$-0.03
Q2 25
$0.67
$-0.04
Q1 25
$-0.04
Q4 24
$-0.09
Q3 24
$-0.04
Q2 24
$1.23
$-0.08
Q1 24
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CHR
CHR
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$689.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$322.1M
$715.5M
Total Assets
$362.7M
$1.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CHR
CHR
ZLAB
ZLAB
Q4 25
$689.6M
Q3 25
$717.2M
Q2 25
$732.2M
Q1 25
$757.3M
Q4 24
$779.7M
Q3 24
$616.1M
Q2 24
$186.1M
$630.0M
Q1 24
$650.8M
Stockholders' Equity
CHR
CHR
ZLAB
ZLAB
Q4 25
$715.5M
Q3 25
$759.9M
Q2 25
$322.1M
$791.7M
Q1 25
$810.8M
Q4 24
$840.9M
Q3 24
$667.7M
Q2 24
$286.1M
$704.2M
Q1 24
$762.2M
Total Assets
CHR
CHR
ZLAB
ZLAB
Q4 25
$1.2B
Q3 25
$1.2B
Q2 25
$362.7M
$1.2B
Q1 25
$1.2B
Q4 24
$1.2B
Q3 24
$985.3M
Q2 24
$333.2M
$987.4M
Q1 24
$988.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CHR
CHR
ZLAB
ZLAB
Operating Cash FlowLast quarter
$3.9M
$-26.0M
Free Cash FlowOCF − Capex
$-26.7M
FCF MarginFCF / Revenue
-21.0%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
0.51×
TTM Free Cash FlowTrailing 4 quarters
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CHR
CHR
ZLAB
ZLAB
Q4 25
$-26.0M
Q3 25
$-32.0M
Q2 25
$3.9M
$-31.0M
Q1 25
$-61.7M
Q4 24
$-55.8M
Q3 24
$-26.8M
Q2 24
$-6.7M
$-42.2M
Q1 24
$-90.1M
Free Cash Flow
CHR
CHR
ZLAB
ZLAB
Q4 25
$-26.7M
Q3 25
$-35.0M
Q2 25
$-33.9M
Q1 25
$-63.2M
Q4 24
$-58.4M
Q3 24
$-28.2M
Q2 24
$-42.9M
Q1 24
$-91.1M
FCF Margin
CHR
CHR
ZLAB
ZLAB
Q4 25
-21.0%
Q3 25
-30.4%
Q2 25
-31.1%
Q1 25
-59.9%
Q4 24
-53.8%
Q3 24
-27.7%
Q2 24
-42.9%
Q1 24
-104.5%
Capex Intensity
CHR
CHR
ZLAB
ZLAB
Q4 25
0.5%
Q3 25
2.6%
Q2 25
2.6%
Q1 25
1.5%
Q4 24
2.4%
Q3 24
1.3%
Q2 24
0.7%
Q1 24
1.1%
Cash Conversion
CHR
CHR
ZLAB
ZLAB
Q4 25
Q3 25
Q2 25
0.51×
Q1 25
Q4 24
Q3 24
Q2 24
-0.54×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CHR
CHR

Segment breakdown not available.

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons